Renal Cell Carcinoma Treatment & Management: Approach Considerations, Surgical Treatment, Molecular-Targeted Agents
The combination of pembrolizumab plus lenvatinib or pembrolizumab plus axitinib is preferred first‑line systemic therapy for metastatic renal cell carcinoma, providing superior progression‑free survival compared with the VEGF‑directed tyrosine kinase inhibitor sunitinib.
The therapeutic approach to renal cell carcinoma (RCC) is guided by stage or degree of tumour dissemination; while >50 % of early‑stage RCC patients are cured, metastatic disease remains largely incurable but can achieve long‑term treatment‑free survival. Standard of care for metastatic RCC includes targeted therapies and immunotherapy.
Effective first‑line therapy improves survival and quality of life for patients with stage IV RCC, a disease for which no curative option exists and survival has historically been limited.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)